Fundraising FoxSerimmune
Goleta, US · 2 known investors
Find your way into Serimmune
Sign up to see every warm intro you have to Serimmune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Serimmune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
Investors · 2
Illumina VenturesreportedFoster City
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$27.5M disclosed across 4 rounds · 2016–2023
▶$11.5MraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$11.5MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Malek FahamExecutive Officer, Director
- Kirstin LoomisDirector
- Nicholas NaclerioDirector
- Bill WelchDirector
- Offering amount
- $16.5M
- Amount sold
- $11.5M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedSep 2020 · 7 investors · BiotechnologyRule 506(b)
▶$12MraisedSep 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen M. KujawaExecutive Officer
- Kristin LoomisDirector
- Nicholas NaclerioDirector
- Noah NasserExecutive Officer, Director
- Patrick DaughertyExecutive Officer, Director
- Jaymie R. SawyerExecutive Officer
- John ShonExecutive Officer
- Bill WelchDirector
- Offering amount
- $23.3M
- Amount sold
- $12M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedJun 2019 · 5 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJun 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kristin LoomisDirector
- Bill WelchDirector
- Nick NaclerioDirector
- Patrick DaughertyExecutive Officer, Director
- John ShonExecutive Officer
- Offering amount
- $7M
- Amount sold
- $1.4M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedJan 2017 · 7 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJan 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kristin LoomisExecutive Officer, Director
- Patrick DaughertyExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $2.5M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Serimmune went on to found or lead other companies.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $224.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who founded Serimmune?
- Serimmune was founded by Patrick Daugherty.
- Who are Serimmune's investors?
- Serimmune's investors include Illumina Innovation, Illumina Ventures.
- How much funding has Serimmune raised?
- Serimmune has disclosed $27.5M raised across 4 rounds.
- Where is Serimmune headquartered?
- Serimmune is headquartered in Goleta, US.